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Abstract
P. vivax infection during pregnancy has been associated with poor outcomes such as ane-
mia, low birth weight and congenital malaria, thus representing an important global health
problem. However, no vaccine is currently available for its prevention. Vir genes were the
first putative virulent factors associated with P. vivax infections, yet very few studies have
examined their potential role as targets of immunity. We investigated the immunogenic
properties of five VIR proteins and two long synthetic peptides containing conserved VIR
sequences (PvLP1 and PvLP2) in the context of the PregVax cohort study including
women from five malaria endemic countries: Brazil, Colombia, Guatemala, India and
Papua New Guinea (PNG) at different timepoints during and after pregnancy. Antibody
responses against all antigens were detected in all populations, with PNG women present-
ing the highest levels overall. P. vivax infection at sample collection time was positively
associated with antibody levels against PvLP1 (fold-increase: 1.60 at recruitment -first
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antenatal visit-) and PvLP2 (fold-increase: 1.63 at delivery), and P. falciparum co-infection
was found to increase those responses (for PvLP1 at recruitment, fold-increase: 2.25). Lev-
els of IgG against two VIR proteins at delivery were associated with higher birth weight (27
g increase per duplicating antibody levels, p<0.05). Peripheral blood mononuclear cells
from PNG uninfected pregnant women had significantly higher antigen-specific IFN-γ TH1
responses (p=0.006) and secreted less pro-inflammatory cytokines TNF and IL-6 after
PvLP2 stimulation than P. vivax-infected women (p<0.05). These data demonstrate that
VIR antigens induce the natural acquisition of antibody and T cell memory responses that
might be important in immunity to P. vivax during pregnancy in very diverse geographical
settings.
Author Summary
Naturally-acquired antibody responses to novel recombinant proteins and synthetic pep-
tides based on sequences from P. vivaxVIR antigens were evaluated in women from five
distinct geographical regions endemic for malaria, during and after pregnancy. Levels of
IgG to VIR antigens were indicative of cumulative malaria exposure and increasedwith
current P. vivax infection and P. falciparum co-infection.Antibody data were consistent
with levels of malaria endemicity and current prevalence in the diverse geographical areas
studied. In addition, the magnitude of IgG response to two VIR antigens at delivery was
associated with higher birth weight. Furthermore, T cell responses to VIR antigens were
naturally induced and their magnitude varied according to P. vivax infectious status.
Peripheral bloodmononuclear cells from uninfected pregnant women from a highly
endemic area produced higher TH1 (IFN-γ) and lower pro-inflammatory cytokines (TNF
and IL-6) upon stimulation with a long synthetic peptide representing conserved globular
domains of VIR antigens than P. vivax-infectedwomen. Data suggest that further investi-
gation on these antigens as potential targets of immunity in naturally-exposed individuals
is warranted.
Introduction
Neglected for a long time, P. vivaxmalaria is raising more attention lately due to the increased
recognition of its burden [1–4] and the renewed call for malaria elimination in endemic areas
where P. vivax is an important source of malaria. Firstly, P. vivax is the most widely-spread of
the human malaria parasites, with an at-risk population of 2.65 billion people [5]. Secondly, P.
vivax infection is not as benign as traditionally believed,with severe malaria affecting a variety
of population groups, including pregnant women in whom P. vivax infection has been associ-
ated with poor outcomes such as anemia, low birth weight (LBW) or congenital malaria [6–13].
The adverse consequences of malaria during pregnancy, the presence of parasites in the pla-
centa and the molecularmechanisms of sequestration (parasite ligand and host receptor) have
been well characterized in P. falciparum but to a lesser degree in the case of P. vivax infection.
In P. falciparum infection during pregnancy, parasites may adhere to placental chondroitin sul-
phate A (CSA) through VAR2CSA, a member of the P. falciparum erythrocytemembrane pro-
tein 1 (PfEMP-1) family [14,15]. Thus, susceptibility to placental malaria has largely been
attributed to a set of P. falciparum strains expressing VAR2CSA. Host immunity to this
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particular parasite protein has been associated with exposure to or protection against P. falcipa-
rum infection during pregnancy [16,17]. There is controversy about P. vivax cytoadherence
properties, although we have reported placental P. vivaxmonoinfections in Papua New Guinea
(PNG) with no signs of placental inflammation [18]. Rosetting seems a frequent cytoadhesive
phenotype during P. vivax infections, which may contribute to the development of anemia in
pregnancy [19,20]. Nevertheless, a P. vivax orthologue of the PfEMP-1 gene family and of
VAR2CSA has not been described in parasites infecting pregnant women.
Like P. falciparum, the P. vivax genome contains subtelomeric multigene families. This
includes the variant vir superfamily [21–23] with 295 vir pertaining to 10 subgroups [22,23].
From a structural point of view, vir genes differ greatly in size (156–2,316 bp in length) and
number of exons (1–5). Unlike PfEMP-1, VIR proteins represent an extremely diverse family
clustered in subgroups, which suggests different subcellular localizations and functions. These
functionsmay include immune evasion [22], although P. vivax vir genes do not undergo allelic
exclusion in contrast to the clonal variant expression of P. falciparum var genes [24,25]. More-
over, VIR proteins can localize to the surface of infected reticulocytes [21,26] and induce the
natural acquisition of antibodies after infection [24,27]. Nevertheless, the host immune
responses to VIR proteins and their association with malaria outcomes have not yet been
extensively characterized, even less in pregnancy, partly due to the extent of their diversity and
the difficulty to express them as recombinant proteins for immunoassays.
We have partially overcome these two problems by using the wheat germ cell-free expres-
sion system and by producing two long synthetic peptides containing conservedVIR sequences
(PvLP1 and PvLP2) based on the P. vivax line Sal-I. This strain is originally from El Salvador,
which was monkey-adapted. To overcome the sequence polymorphisms, we determined con-
served globular domains of presently unknown function to synthesize PvLP1 and PvLP2 for
testing in immune-epidemiological field studies with parasites from different origins.
A recent meta-analysis has highlighted the necessity of cohort studies representing diverse
geographical regions in the field of P. vivax infections, to increase the body of evidence for pro-
tective immunity [28]. As part of the PregVax project, a multicenter study aimed at describing
the burden of P. vivaxmalaria in pregnancy, we set out to study naturally acquired immune
responses to VIR proteins during pregnancy. Women from five different P. vivax endemic coun-
tries in America (Guatemala, Colombia, Brazil), Asia (India) and South Pacific (PNG) were
enrolled and antigen-specific immune responses assessed.We usedVIR-based recombinant pro-
teins as well as PvLP1 and PvLP2 for antibody and cellular immunoassays. We demonstrate that
despite the large diversity of vir sequences, women from all regions mounted antibody responses
to the VIR antigens that increasedwith P. vivax infection and past exposure.Moreover, women
from the highest endemic region (PNG) had detectable VIR-specific cellular memory immune
responses with distinct patterns according with P. vivax infection status. Altogether, data indi-
cate that VIR antigens might be targets of immunity to P. vivax during pregnancy.
Results
Expression of VIR proteins
A total of 16 vir genes were selected to be cloned and expressed. Twelve one-exon genes were
selected for practical reasons as genomic DNA could be used as template (S1 Table). In addition,
four vir genes were selected after a protein BLAST against VAR2CSA domains, presenting 18.8–
30.6% protein identity (S2 Table). Because the var2csa-homology regions of vir genes were
always located in exon 2, only this exon was cloned. Of these 16 vir genes, four one-exon vir
genes were discarded for protein expression: two of them (PVX_006080 and PVX_241290)
could not be cloned as the PCR reaction did not work and another two (PVX_045190 and
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PVX_106220) did not present the expected sequence after cloning.With the classical E. coli
expression system, PVX_086890 and PVX_069690 were poorly induced; and PVX_015640,
PVX_067190, PVX_090290 and PVX_115485 were insoluble. Attempts to purify the six remain-
ing partially soluble VIR proteins expressed in E. coli resulted in very low yields and not
completely clean proteins. Therefore, these six VIR proteins were cloned in the pIVEX vector
and further expressed in the cell-freewheat germ system but PVX_112125 showed mutations in
the sequence. Thus, five vir genes were successfully expressed in the wheat germ cell-free expres-
sion system: vir25 (vir25-related, PVX_001610, group one-exon); vir14 (vir14-related,
PVX_101615, group one-exon); vir2 (vir2/15-like, PVX_107750, group var2csa homology), vir24
(vir24-like, PVX_093720, group var2csa homology) and vir5 (vir5-related, PVX_124715, group
var2csa homology). Soluble proteins were obtained of predicted sizes as detected by SDS-PAGE
(Fig 1). Because expression of VIR proteins was not very productive, we designed two peptides
containing conservedVIR sequences in order to perform the immunological assays.
Characteristics of the study population
A total of 1,511 peripheral blood samples collected at different time points (recruitment, deliv-
ery or postpartum) corresponding to 1,056 women, were analyzed for antibody responses.
Unfortunately many of our samples were not paired due to low follow-up rates. The study pop-
ulation characteristics at baseline by country are provided in S3 Table. The infection rates by
country and time-point are provided in Table 1. The amount of VIR14, VIR2 and VIR24 pro-
teins produced was not sufficient to measure antibodies to them in all samples, therefore enrol-
ment-delivery-postpartummatching samples were prioritized. The numbers of plasma
samples per country for which anti-VIR antibody data were generated against each antigen
and at different time point are summarized in S4 Table. For cellular assays, 53 samples (any
gestational age including delivery, 18 P. vivax PCR negative, 28 P. vivax PCR positive, 7
unknown infection status) from the PNG pregnant cohort were included in the analyses.
Fig 1. Expression of VIR proteins and GST in the wheat germ cell-free system. Five VIR proteins were
expressed using the cell-free wheat germ system. Soluble extracts of each were analyzed by western blot
using an anti-GST antibody. Purified soluble extracts were analyzed by SDS-PAGE and stained with Blue
Coomassie Blue. Molecular weights (MW) markers in kilo-Daltons are shown in the third column, and soluble
VIR-GST for the five fusion proteins of predicted sizes are marked with an arrow in columns 1,2,4,5 and 6.
GST alone also expressed as a control, is shown in column 7.
doi:10.1371/journal.pntd.0005009.g001
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VIR antigens are targets of naturally-acquired antibodies
Antibody responses to all VIR antigens were detected (value above negative control cutoff) in
all sites and timepoints, except VIR25 and VIR5 at postpartum in India (IN) (Fig 2). IgG levels
Table 1. Infection rate by timepoint and country in a random subset of samples for which microscopy and/or PCR data was available.
RECRUITMENT Brazil Colombia Guatemala India PNG p-value
Pv (microscopy)a negative 117 (96%) 204 (96%) 172 (99%) 134 (100%) 135 (99%) 0.0120c
positive 5 (4%) 8 (4%) 1 (1%) 0 (0%) 1 (1%)
Pv (PCR)a negative 112 (91%) 192 (90%) 148 (86%) 130 (99%) 71 (95%) 0.0008b
positive 11 (9%) 21 (10%) 25 (14%) 1 (1%) 4 (5%)
Any Pv negative 121 (91%) 195 (90%) 148 (86%) 133 (99%) 133 (97%) < 0.0001b
positive 12 (9%) 22 (10%) 25 (14%) 1 (1%) 4 (3%)
Pf (microscopy)a negative 126 (100%) 202 (95%) 173 (100%) 134 (100%) 123 (90%) < 0.0001b
positive 0 (0%) 10 (5%) 0 (0%) 0 (0%) 13 (10%)
Pf (PCR)a negative 122 (99%) 195 (92%) 170 (98%) - 69 (92%) < 0.0001c
positive 1 (1%) 18 (8%) 3 (2%) - 6 (8%)
Any Pf negative 132 (99%) 199 (92%) 170 (98%) 134 (100%) 121 (88%) < 0.0001b
positive 1 (1%) 18 (8%) 3 (2%) 0 (0%) 16 (12%)
DELIVERY Brazil Colombia Guatemala India PNG p-value
Pv (microscopy)a negative 65 (93%) 105 (93%) 104 (99%) 100 (99%) 133 (99%) 0.0031c
positive 5 (7%) 8 (7%) 1 (1%) 1 (1%) 1 (1%)
Pv (PCR)a negative 59 (88%) 83 (86%) 76 (82%) 88 (99%) 60 (92%) 0.0036b
positive 8 (12%) 13 (14%) 17 (18%) 1 (1%) 5 (8%)
Any Pv negative 67 (89%) 102 (87%) 88 (84%) 99 (98%) 128 (96%) 0.0011b
positive 8 (11%) 15 (13%) 17 (16%) 2 (2%) 6 (4%)
Pf (microscopy)a negative 72 (100%) 109 (96%) 105 (100%) 101 (100%) 128 (96%) 0.0075c
positive 0 (0%) 5 (4%) 0 (0%) 0 (0%) 6 (4%)
Pf (PCR)a negative 67 (100%) 89 (93%) 90 (97%) - 62 (95%) < 0.0001c
positive 0 (0%) 7 (7%) 3 (3%) - 3 (5%)
Any Pf negative 75 (100%) 110 (94%) 102 (97%) 101 (100%) 126 (94%) 0.0103c
positive 0 (0%) 7 (6%) 3 (3%) 0 (0%) 8 (6%)
POST-PARTUM Brazil Colombia Guatemala India PNG p-value
Pv (microscopy)a negative 38 (93%) 5 (62%) 59 (98%) 7 (58%) 53 (98%) < 0.0001b
positive 3 (7%) 3 (38%) 1 (2%) 5 (42%) 1 (2%)
Pv (PCR)a negative 38 (95%) 2 (40%) 37 (79%) 5 (38%) 29 (100%) 0.0001b
positive 2 (5%) 3 (60%) 10 (21%) 8 (62%) 0 (0%)
Any Pv negative 39 (93%) 6 (60%) 50 (83%) 8 (62%) 54 (98%) < 0.0001c
positive 3 (7%) 4 (40%) 10 (17%) 5 (38%) 1 (2%)
Pf (microscopy)a negative 42 (100%) 10 (100%) 60 (100%) 13 (100%) 51 (94%) 0.1326c
positive 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (6%)
Pf (PCR)a negative 39 (98%) 4 (80%) 45 (96%) - 28 (97%) < 0.0001b
positive 1 (2%) 1 (20%) 2 (4%) - 1 (3%)
Any Pf negative 41 (98%) 9 (90%) 58 (97%) 13 (100%) 51 (93%) 0.5207 c
positive 1 (2%) 1 (10%) 2 (3%) 0 (0%) 4 (7%)
a number (percentage) in columns.
b Chi-squared test.
c Fisher’s exact test.
Pv: P. vivax infection. Pf: P. falciparum infection; PNG: Papua New Guinea.
doi:10.1371/journal.pntd.0005009.t001
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Fig 2. Antibody responses to VIR antigens. Human IgG antibodies against VIR proteins and peptides
were detected by Luminex in peripheral blood at different timepoints: A) recruitment (first antenatal visit) (top
panel), B) delivery (middle panel) and C) postpartum (after puerperium) (lower panel). Antibody levels are
represented as median fluorescence intensity (MFI). Reactivity (MFI) against GST was subtracted from MFI
values obtained against individual recombinant proteins. Median (white line), and 25th and 75th percentiles
(lower and upper hinge respectively) are represented as boxes. Outside values are not displayed in the
graph. Numbers below boxes represent percentage of positive responses, calculated as number of plasmas
VIR Proteins and Vivax Malaria Immunity in Pregnancy
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to all VIR antigens differed among countries at all timepoints (except VIR25 at postpartum)
(one-way ANOVA p<0.05). PNG presented the highest magnitudes and prevalence, followed
by Guatemala (GT).
Overall, VIR25 appeared to be the most broadly recognized antigen, with significant
responses across all endemicities, even in countries like Brazil (BR) and IN where IgG responses
to the other VIR antigens were very low (Fig 2). In addition, VIR14 and VIR2 showed consistent
and comparable responses in PNG and GT at all timepoints, stronger than those to VIR25, and
for VIR2 a peak was also detected at postpartum in Colombia (CO). Finally, VIR5 and PvLP2
only appeared to be considerably recognizedby plasma from PNG, and PvLP2 (and PvLP1) also
in CO at postpartum. The lowest responses were measured for VIR24, only detected at moderate
levels for PNG. Of note, anti-VIR seroprevalence was in range with other P. vivax antigens such
as Pv200L: BR: 7%; CO: 35%; GT: 40%; IN: 5%; PNG: 76%.
At recruitment, IgG responses to VIR proteins were closely correlated (Table 2), but they
correlated poorly with antibody responses to VIR synthetic peptides or other P. vivax antigens
such as Pv200L, which corresponds to a fragment of the merozoite surface protein 1. PvLP2
presented the highest correlation with Pv200L (Table 2) and other P. vivax antigens.
We considered whether anti-VIR responses were due to cross reactivity with other Plasmo-
dium antigens. To assess this, we studied the correlation between anti-VIR responses and anti-
body responses to 9 P. vivax and 6 P. falciparum additional antigens. Of note, low correlations
were found between anti-VIR responses and other anti-Plasmodium responses, suggesting that
there was no cross-reactivity (S5 table).
There were higher levels of anti-VIR24 IgGs at delivery, and more anti-VIR2, anti-VIR25
and anti-PvLP1 antibodies at postpartum, compared to recruitment levels, although overall dif-
ferences using theWald test were only significant for PvLP1 (S6 Table).
Association between antibody levels and pregnancy variables and
outcomes
We assessed how different pregnancy variables affected the IgG responses to VIR antigens.
Antibody levels to VIR5 were significantly associated with gravidity (proportional differences
samples with MFI values above the mean plus 3 standard deviations of negative controls (cutoff). Cutoff for
India samples was calculated with negative samples analyzed at this site and therefore differed from those
used for the other sites. p corresponds to one-way ANOVA plus Bonferroni pairwise correction. Differences
only displayed versus PNG. *p<0.05, **p<0.01, ***p<0.001 (adjusted p-values multiple comparisons).
Sample size for each country, timepoint and antibody is provided in S4 Table. BR: Brazil; CO: Colombia; GT:
Guatemala; IN: India; PNG: Papua New Guinea.
doi:10.1371/journal.pntd.0005009.g002
Table 2. Correlation of IgG antibody responses to VIR antigens at recruitment.
VIR25 0.50
VIR5 0.56 0.52
VIR2 0.70 0.71 0.57
VIR14 0.67 0.65 0.55 0.91
PvLP1 0.08 0.15 0.17 -0.02 -0.08
PvLP2 0.17 0.15 0.23 0.11 0.06 0.61
Pv200L 0.24 0.12 0.22 0.25 0.21 0.47 0.62
VIR24 VIR25 VIR5 VIR2 VIR14 PvLP1 PvLP2
Spearman’s correlation coefficient is displayed in the cells. The colour scale ranges between the dark grey (Spearman´s rho=|1|) and white (rho=0).
Samples included in this analysis belonged to recruitment. Sample sizes for each antibody are provided in S4 Table.
doi:10.1371/journal.pntd.0005009.t002
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by [category group of previous pregnancies] [0]: 1; [1–3]: 1.43, 95% CI: 0.91–2.25; [4+]: 0.71,
95% CI: 0.34–1.48, p=0.033). IgG responses to PvLP1 and PvLP2 were significantly associated
with present malaria infections (Table 3). Of note, the association with co-infections (P. vivax
and P. falciparum) was higher than with mono-infections (P. vivax alone). However, sample
size for co-infectionswas small, especially at delivery, and these results should be considered
cautiously. The magnitude of VIR-specific IgG response did not show associations with age
and gestational age (p>0.05).
We also analyzed the association between antibody levels at recruitment and future infec-
tion (at delivery).Women with higher PvLP1 antibody levels at recruitment had a higher prob-
ability of having a P. vivax infection at delivery (per doubling antibody levels, OR=1.84, 95%
CI=1.11; 3.04, p=0.017, adjusted analysis).
Finally, we studied the association between antibody levels and pregnancy outcomes, i.e.
hemoglobin (Hb) levels and birth weight. A borderline significant positive association between
PvLP2 antibody levels at recruitment and birth weight was observedby unadjusted regression
analyses (Table 4). At delivery, IgG responses against two VIR proteins with homology to
VAR2CSA (VIR2 and VIR24) were positively associatedwith birth weight in the adjusted analysis
(Table 4). No associations were found between antibody levels and Hb levels at delivery (p>0.05).
Cellular responses to PvLP1 and PvLP2
Peripheral bloodmononuclear cells (PBMC) from PNG women with current P. vivax infection
had a significantly lower percentage of IFN-γ-producing CD4+ and CD8+ T cells than unin-
fected women when stimulated with PvLP2, as assessed by intracellular cytokine staining by
flow cytometry (Fig 3). No differences in % IFN-γ+ CD4+ T cells between infected and non-
infected women were observedwhen stimulating PBMCs with PvLP1 or in the medium and
anti-CD3 controls, and significant but much lower differences compared to PvLP2 stimulus
were observed in % IFN-γ+ CD8+ T cells for PvLP1 and medium control (Fig 3).
We alsomeasured the concentration of cytokines, chemokines and growth factors secreted in
PBMC cultured either with medium, PvLP1 or PvLP2. Infected women producedmore G-CSF
and IL-4 than those from uninfectedwomen, independently of the stimulus (Table 5). In addi-
tion, supernatants containedmore IFN-γwhen PBMCwere cultured with medium or PvLP2,
Table 3. Association of pregnancy variables with antibody levels.
Recruitmenta Deliveryb
Effc 95% CI p Eff 95% CI p
PvLP1 Pv-/Pf- 1 <0.001 1 0.033
Pv+/Pf- 1.60 1.23; 2.07 1.11 0. 75; 1.66
Pv-/Pf+ 1.20 0.87; 1.67 2.08 1.05; 4.11
Pv+/Pf+ 2.25 1.01; 5.00 7.51 1.14; 49.44
PvLP2 Pv-/Pf- 1 0.161 1 <0.001
Pv+/Pf- 1.30 0.97; 1.73 1.63 1.09; 2.63
Pv-/Pf+ 1.25 0.87; 1.80 4.20 2.04; 8.61
Pv+/Pf+ 1.57 0.64; 3.83 11.27 1.54; 82.60
Adjusted regression models were estimated for all combinations of positivity (+) and negativity (-) to P. vivax (Pv) and P. falciparum (Pf) infections.
a Pv-/Pf- N=672; Pv+/Pf- N=52; Pv-/Pf+ N=33; Pv+/Pf+ N=5.
b Pv-/Pf- N=425; Pv+/Pf- N=25; Pv-/Pf+ N=8; Pv+/Pf+ N=1.
c Adjusted effect represents the fold-increase in antibody levels (MFI) per belonging to each category, after adjusting for the following variables: country of
origin, age, gravidity (number of previous gestations), gestational age at recruitment and present malaria infection.
doi:10.1371/journal.pntd.0005009.t003
VIR Proteins and Vivax Malaria Immunity in Pregnancy
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005009 October 6, 2016 8 / 20
although the median value was the same, suggesting that differenceswere not very high. Of note,
PBMCs stimulated only with PvLP2 secreted specificallymore pro-inflammatory cytokinesTNF,
IL-6 and regulatory cytokine IL-10 in the infected group than in the uninfected group, although
the difference did not reach statistical significance for IL-10 (p=0.062). No differences between
the infected and uninfected cohorts were observed in the anti-CD3 control, although overall val-
ues in this positive control were higher than in the other three culture conditions.
Discussion
Considering the large genetic diversity of P. vivax strains [29] and the effect that polymor-
phisms in host genes such as HLA can have on immune responses to certain antigens [30], it is
Fig 3. In vitro production of IFN-γ by peripheral blood mononuclear cells (PBMC) in response to VIR peptide stimulation.
Intracellular production of IFN-γ by PBMCs was analyzed by flow cytometry. Box plots of the percentages of IFN-γ-producing cells from total
CD4+ (A) or CD8+ (B) T cells are shown after PBMCs were cultured in the presence of PvLP1, PvLP2 or medium alone. In C), IFN-γ-
producing cells from total CD4+ or CD8+ T cells are shown after culture in the presence of ant-CD3. IFN-γ production was compared
between P. vivax infected (I, N=28) and uninfected (U, N=18) pregnant women; p corresponds to Mann-Whitney test. Median (middle line in
white), and 25th and 75th percentiles (lower and upper hinge, respectively) are represented in the box. Outside values are excluded.
doi:10.1371/journal.pntd.0005009.g003
Table 4. Association of antibody responses with birth weight.
Recruitment Delivery
Unadjusted Adjusted Unadjusted Adjusted
Diffa 95%CI p Diff 95%CI p Diff 95%CI p Diff 95%CI p
VIR14b 6.7 -16.71; 30.02 0.578 9.5 -13.85; 32.85 0.427 19.8 -5.96; 45.45 0.135 23.9 -1.91; 49.62 0.073
VIR25c -5.0 -17.56; 7.48 0.431 -7.8 -20.70; 5.12 0.238 -10.5 -22.12; 1.15 0.078 -7.1 -19.17; 4.95 0.249
VIR2b -1.4 -23.97; 21.09 0.900 6.8 -15.40; 29.05 0.549 17.6 -6.95; 42.18 0.163 26.6 2.48; 50.72 0.033
VIR24b 12.3 -12.65; 37.28 0.336 17.3 -8.05; 42.60 0.185 22.9 -2.29; 47.99 0.078 27.0 1.93; 52.14 0.038
VIR5c 8.6 -5.24; 22.43 0.224 4.6 -9.67; 18.90 0.527 5.0 -7.82; 17.78 0.446 4.8 -8.73; 18.32 0.488
PvLP1c 14.8 -23.79; 53.43 0.452 11.6 -28.11; 51.31 0.567 -16.9 -51.45; 17.58 0.337 -23.7 -59.48; 12.06 0.195
PvLP2c 34.8 -1.67; 71.16 0.062 24.7 -12.38; 61.68 0.193 0.6 -31.83; 33.07 0.970 4.4 -28.62; 37.37 0.795
Simple and adjusted regression models were estimated to establish the association between birth weight and the various IgG antibody levels at recruitment
and at delivery, adjusting for the following variables: country of origin, age, gravidity (number of previous gestations), gestational age at recruitment and
present malaria infection. Displayed in bold if p<0.07.
a Difference in birth weight (g) per duplicating antibody levels.
b N=104 at recruitment and N=101 at delivery.
c N=382 at recruitment and N=449 at delivery.
doi:10.1371/journal.pntd.0005009.t004
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important to evaluate antibody and cellular immune responses to potential targets of immunity
in different geographical populations. Here, significant levels of anti-VIR antibodies were
detected in pregnant women from five countries with very diverse endemicity and transmission
rates, further supporting the immunogenic properties of VIR antigens previously reported in
non-pregnant Brazilian women [21,24,27]. This is remarkable if we consider that the Sal-I
genome was used as a template for the production of all recombinant VIR proteins and sug-
gests that despite the high sequence variability in the VIR proteins and the P. vivax circulating
strains, B cell epitopes might be sufficiently conserved.This is further supported by the immu-
nogenicity of long synthetic peptides representing conservedglobular domains of VIR proteins,
Table 5. Median concentration (pg/mL) values for each cytokine, chemokine and growth factor in supernatants from infected (I) and uninfected
(U) groups.
MEDIUM PvLP1 PvLP2 anti-CD3
U I pa U I p U I p U I p
EGF 51 41 0.386 40 44 0.725 81 42 0.217 65 55 0.561
Eotaxin 13 3 0.248 13 3 0.333 13 3 0.349 13 3 0.228
FGF 18 17 0.259 15 17 0.282 15 16 0.541 36 30 0.379
G-CSF 129 162 0.045 116 157 0.046 112 169 0.005 211 221 0.903
GM-CSF 38 38 0.088 38 38 0.589 38 38 0.789 94 98 0.685
HGF 204 182 0.329 243 132 0.180 225 147 0.374 362 268 0.357
IFN-α 215 208 0.348 201 204 0.858 190 213 0.673 272 234 0.552
IFN-γ 13 13 0.044 13 13 0.088 13 13 0.024 868 607 0.291
IL-10 54 59 0.576 33 44 0.460 35 71 0.062 596 429 0.358
IL-12 56 55 0.891 56 42 0.916 55 52 0.983 168 112 0.626
IL-13 71 72 0.916 71 72 0.466 67 72 0.712 286 224 0.330
IL-15 147 86 0.142 313 156 0.093 313 147 0.113 366 329 0.358
IL-17 125 41 0.440 125 77 0.095 125 35 0.264 246 211 0.561
IL-1β 71 71 0.983 63 63 0.841 63 75 0.768 300 286 0.957
IL-1Rα 1503 1521 0.784 1446 1559 0.343 1503 1558 0.442 6192 4975 0.291
IL-2 16 8 0.029 9 8 0.217 11 7 0.164 1653 906 0.224
IL-2R 138 173 0.688 150 150 0.634 150 164 0.744 502 444 0.776
IL-4 13 44 0.029 14 40 0.039 13 44 0.022 229 154 0.379
IL-5 8 8 0.101 8 8 0.014 8 8 0.318 258 119 0.076
IL-6 1383 2182 0.225 817 1649 0.454 1419 2406 0.046 2643 2946 0.646
IL-7 75 75 0.946 75 75 0.465 75 75 0.674 76 102 0.348
IL-8 64000 64000 0.699 64000 64000 0.248 64000 64000 0.745 64000 64000 0.152
IP10 6 6 0.598 7 7 0.760 6 6 0.720 99 100 0.850
MCP-1 18640 13770 0.286 13911 14766 0.727 12752 17351 0.453 19201 18440 0.869
MIG 113 113 0.439 113 113 0.319 113 113 0.430 407 298 0.433
MIP1-α 1251 1597 0.924 866 1004 0.808 1291 1421 0.327 4893 5172 0.607
MIP1-β 1254 1152 0.792 678 1028 0.562 1101 1509 0.242 3855 5274 0.358
Rantes 203 158 0.620 104 121 0.907 80 140 0.393 454 387 0.570
TNF 62 47 0.792 32 39 0.422 39 64 0.040 2741 1568 0.111
VEGF 72 89 0.941 67 78 0.332 63 101 0.116 206 177 0.589
a U-Mann-Whitney test. In bold if p<0.065.
G-CSF: granulocyte colony-stimulating factor, GM-CSF: granulocyte macrophage colony-stimulating factor, IFN: interferon, IL: interleukin, TNF: tumor
necrosis factor, IP: IFN-γ-inducible protein, MCP: monocyte chemo attractant protein, MIG: monokine induced by IFN-γ, MIP: macrophage inflammatory
protein, EGF: epidermal growth factor, FGF: fibroblast growth factor, HGF: hepatocyte growth factor, VEGF: vascular endothelial growth factor.
doi:10.1371/journal.pntd.0005009.t005
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particularly PvLP2.We cannot, however, exclude the possibility that low responses to some
VIR proteins in particular settings are due to lack of VIR expression or that they contain less B-
cell epitopes as opposed to the inability to develop a VIR-specific immune response upon expo-
sure to that variant.
Expressing recombinant Plasmodium proteins using different expression vectors has shown
to be a challenging endeavor [31], especially achieving expression of soluble and correctly
folded proteins is even more difficult. The cell-free wheat germ expression system used here
has proven to be an excellent system to produce soluble and correctly folded proteins [32,33].
In fact, expression of enzymes from the human genome consistently showed that they retain
enzyme activity [34]. In spite of these advantages, vir genes are highly AT-rich and several dif-
ferent attempts to express all the genes listed in S1 and S2 Tables using this or other systems
such as cell-free and cell-basedE. coli have failed.
PNG presented the highest intensity and prevalence of antibody responses against all anti-
gens, despite P. vivax infection rates not beingmuch higher at the time of the study within this
cohort than in the other five countries [35]. The fact that asymptomatic infected women were
not given treatment in PNG does not explain this difference, as the prevalence of P. vivax infec-
tion by microscopy in PNG was only 1%. Nevertheless, antibodies are a reflection of cumula-
tive exposure, and PNG is indeed the country among the five with the highest malaria
endemicity historically, even if during the PregVax study P. vivax prevalence was lower than in
the past. In addition, regression analyses showed that co-infectionswith P. falciparum had a
higher positive association with PvLP1 and PvLP2 antibody levels than P. vivaxmono-infec-
tions. PNG had the highest P. falciparum microscopic infection rate in this cohort, suggesting
these may boost anti-P. vivax responses. In our cohort we could rule out mostly although not
totally undiagnosed submicroscopic co-infection and vir genes do not have orthologues in P.
falciparum. It might be that this co-infection boosting effect is due to P. vivax-specificB cell
bystander activation by noncognate T cells, which could be induced under conditions of persis-
tent priming by P. falciparum antigens [36,37]. If this was the case, it may be interesting to con-
sider this effect in programmatic terms regarding the search of a malaria vaccine. However, it
is also possible that co-infections and higher antibody levels are just two parallel markers of
higher previous exposure in some women.
Plasmas from GT also presented significant levels of IgG antibodies to various VIR proteins.
This is consistent with P. vivax positivity rates by PCR at the population level, which were the
highest in GT and PNG in the whole PregVax cohort. Infections in GT were largely submicro-
scopic but sufficient to induce detectable antibody responses. There was heterogeneity with
regards to recognition of the VIR antigens among countries. VIR25 was the most broadly
immunogenic, being recognized in distant geographical regions, suggesting the presence of
conserved and/or cross-reactive epitopes within its sequences. However VIR14 and VIR2
induced the highest levels of antibodies, though restricted to the two most endemic countries.
Those three proteins (VIR25, VIR14 and VIR2) appeared to induce longer-lived antibodies as
they were clearly detected in populations with high infection rates in the past but low at the
time of sampling. Antibodies to VIR24, VIR5 and PvLP2 were only clearly present in PNG,
and this might indicate geographical diversity in immunogenicity of epitopes and/or their even
longest-living nature. IgG antibodies against PvLP1 and PvLP2 were detected in all countries
and timepoints but not at high levels. A peculiar pattern was observed in CO, where a signifi-
cant increase in responses to most VIR antigens, but particularly VIR2 and PvLP2, occurred at
postpartum. This likely reflects increased parasite prevalence at a population level at this time
rather than a booster of VIR responses after pregnancy. However, at an individual level we did
not find an association between antibodies to VIR proteins and infection status, which proba-
bly reflects the diversity of vir genes in the P. vivax genome [38]. In contrast, levels of PvLP1
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and PvLP2 were associated with present vivax malaria infections. Both antibody levels but spe-
cially anti-PvLP2 correlated well with other markers of malaria exposure. This suggests that
the design of these peptides (based on conserved sequences)might have helped overcome the
problem of having a large and variable gene family. Thus, collectively the data showed that VIR
antigens could be markers of exposure at a population level.
We also assessed association between antibodies and protection at the individual level,
although this is often difficult as heterogeneity of exposure is not properly assessed and
accounted for in field designs. In fact, higher PvLP1 antibodies at recruitment were associated
with more risk of infection at delivery, being a correlate of risk rather than of immunity. We
have previously reported that higher levels of antibodies in some individuals may indicate
those who have had previous malaria episodes and are at higher risk of future episodes if past
exposure is not well adjusted for [39,40]. Nevertheless, we also found some indications for a
potential protective role of VIR antibodies in malaria in pregnancy outcomes: (i) a borderline
significant positive association between PvLP2 antibody levels at recruitment and birth
weight and (ii) a positive association of antibody levels to VIR2 and VIR24 (of partial
sequence homology to P. falciparum VAR2CSA domains) at delivery and birth weight. Pla-
cental P. vivax infection has been reported [18], as well as P. vivax adhesion to CSA [19] and
inhibition of P. vivax cytoadhesion using soluble CSA [41]. However, whether VIR2 and
VIR24 proteins also bind CSA and are implicated in vivax malaria during pregnancy remains
speculative. Unfortunately, our study was not designed to demonstrate any protective role of
antibody responses to VIR antigens in vivax malaria and therefore we cannot draw any
conclusion.
We present some evidence supporting a relationship between antigen-specific cytokine
responses, infection and immunity in PNG pregnant women. Our data show lower PvLP2-spe-
cific IFN-γ+ CD4+ T cell frequencies and higher secretion of TNF, IL-6 and IL-10, in P. vivax-
infected pregnant women compared to uninfectedwomen and this was not seen for PvLP1 or
the control stimuli. IFN-γ has been shown to be essential for controlling experimentalmalaria
infections in mice (reviewed in [42]) and clinical P. falciparum infections in humans [43,44],
and IL-10 is a key regulatory cytokine that prevents excessive inflammation but might contrib-
ute to the lack of control of infections. Thus, the fact that non-infectedwomen had higher
PvLP2-specificTH1 cell frequencies and lower IL-10 production could mean that cellular
responses induced by this antigen (for instance by a potential vaccine) could help in controlling
vivax infections. Nevertheless, we also observedPvLP2-specific increase of pro-inflammatory
cytokines IL-6 and TNF in infected women. IL-6 has been shown to skew T cell differentiation
towards TH2 and TH17 [45], which would explain why we observe a decrease of TH1 frequen-
cies. Thus we can assume that VIR epitopes present in PvLP2 trigger the natural acquisition of
cellular memory immune responses, but whether these are protective or just markers of expo-
sure can not be concluded from the data presented.
This study presents some limitations. First, samples were not fully paired and sample size
was different for some antigens/analyses. Unfortunately, many of these women lived in rural
areas far from the hospital. It is highly complex to get full attendance to all antenatal clinics
and, after puerperium, is evenmore complicated. In spite of this, we believe the cohort is quite
unique and very valuable to demonstrate the immunogenicity of VIR antigens in different geo-
graphical settings. Second, due to its exploratory nature, we did not have statistical power to
demonstrate strong associations between anti-VIR immune responses and protection against
infection nor poor outcomes, as it was designed to be a first descriptive investigation of adap-
tive immune response (antibody and T cells) to VIR antigens during pregnancy. Third, multi-
ple comparisons were not corrected for in all statistical assays and results are interpreted for
internal coherence and biological plausibility.
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In summary, we present the first comprehensive study on immune responses to VIR anti-
gens demonstrating that VIR sequences are the target of the natural acquisition of antibody
and cellular responses affected by exposure to malaria infection in five distinct endemic areas.
VIR 25 seems to be broadly recognized and we demonstrate that PvLP1 and PvLP2 can be used
to profile antibody and cellular immune responses to VIR sequences, overcoming the problem
of the large number of diverse VIR proteins. Based on our findings and the large burden of
vivaxmalaria, we believe that larger prospective cohort immune epidemiological studies are
needed to specifically address whether VIR-based antigens are targets of protective immunity
against the neglectedP. vivax parasite and could be considered as candidates for vaccine devel-
opment towards malaria elimination.
Methods
Study design and population
This study was performed in the context of the PregVax project (FP7-HEALTH-201588,
www.pregvax.net), a health facility-based cohort study of pregnant women to describe the
burden and impact of P. vivax in pregnancy, conducted between 2008 and 2012 in five
endemic countries: BR, CO, GT, IN and PNG. Approximately 2,000 women per country were
enrolled at the first antenatal visit (recruitment), and followed up until delivery. Symptomatic
Plasmodium spp. infections at any time during pregnancy were also recorded though passive
case detection. A random subpopulation corresponding to 10% of the entire PregVax cohort
was allocated to the “immunology cohort” and was further followed up until at least 10 weeks
after delivery (postpartum group). In all visits, Hb levels, P. vivax and P. falciparum parasite-
mias by blood smear and malaria symptoms were assessed. Giemsa-stained thick and thin
blood slides were read onsite followingWHO standard quality-controlled procedures to
establish parasite presence. External validation of a subsample of blood slides from each
country was done at the Hospital Clinic and at the Hospital Sant Joan de Deu, in Barcelona,
Spain. Birth weight was recorded.Women with a positive smear were treated according to
national guidelines, except in PNG where blood smears could not be read at the moment of
the visit for logistical reasons (only symptomatic women were thus treated after confirmation
of infection by rapid diagnostic test). The protocol was approved by the national and/or local
ethics committees of each site, the CDC IRB (USA) and the Hospital Clinic Ethics Review
Committee (Barcelona, Spain). Written informed consent was obtained from all study
participants.
A venous blood sample (5–10 mL) was collected aseptically in heparinized tubes from the
“immunology cohort” at recruitment, delivery and postpartum visits. Submicroscopic P. vivax
and P. falciparum infections were also determined by real time-polymerase chain reaction
(PCR), except for the Indian samples, where only P. vivax infectionwas examined. Submicro-
scopic infections were only analyzed in a random sub-sample of the cohort. Additionally,
blood samples (10 mL) were collected from 39 malaria naïve donors at the blood bank in Hos-
pital Clinic (Barcelona, Spain), and used as negative controls.
Processing of plasma and PBMC
Plasma was separated by centrifugation and stored at -80°C. Blood cells from PNG were further
fractioned in a density gradient medium (Histopaque-1077, Sigma-Aldrich) to obtain PBMCs
and stored in liquid nitrogen. Samples from GT, CO, BR and PNG were analyzed at ISGlobal
(Barcelona, Spain) while plasmas from IN were analyzed in Delhi.
VIR Proteins and Vivax Malaria Immunity in Pregnancy
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005009 October 6, 2016 13 / 20
Recombinant proteins and long synthetic peptides
Vir genes were amplified from genomic DNA (Sal I strain) by PCR using “PCR Supermix”
(Life Technologies). PCR products were introduced in the pIVEX1.4d vector (Roche) previ-
ously modified by inserting glutathione S-transferase (GST) after the 6xHis tag sequence.
Authenticity of all clones encodingGST-VIR fusion proteins was confirmed by double-strand
sequencing before expression in the wheat germ system. Thus, GST-fusion proteins contain
open reading frames encoding the predicted VIR proteins.
Primers used for gene amplification are listed in S1 and S2 Tables.
Proteins were expressed with a GST tag using the wheat germ cell-free system as described
[46]. Expressed proteins were purified on GST SpinTrap purification columns (GE Health-
care), and eluted proteins were dialyzed in phosphate buffered saline (Tube-O-DIALYZER,
GBiosciences).GST was also expressed separately for immune-reactivity control. Pv200L (P.
vivaxmerozoite surface protein 1, fragment 121–416) was produced as previously described
[47]. The rest of Plasmodium antigens were produced as describedpreviously [48]. The design
and synthesis of P. vivax long synthetic peptides (PvLP) representing conserved central core
(PvLP1) and C-terminal (PvLP2) VIRmotifs, has been reported previously [26]. The sequences
are detailed in S7 Table.
Quantification of IgG antibodies
Measurement of plasma IgG antibodies was performed by multiplex suspension array using
the Luminex technology, as described [46]. MagPlex magnetic carboxylatedmicrospheres
(Luminex Corporation, TX, USA) were covalently coated with 3 μg of protein/peptide per 1.1–
1.4 million beads followingmanufacturer’s instructions. Beads were quantified in a Guava
Flow Cytometer (Millipore) and mixed in equal amounts. A unique batch of microspheres was
prepared for the whole study, including the samples analyzed in IN. Circa 1000 beads per ana-
lyte were incubated with plasma (1:100 dilution) in duplicates, and subsequently with anti-
human IgG-biotin (Sigma-Aldrich), followed by streptavidin-conjugated R-PE (Fluka, Madrid,
Spain). Beads were acquired on the BioPlex100 system (Bio-Rad, Hercules, CA), and results
expressed as median fluorescence intensity of duplicates. Value against GST alone was sub-
tracted for VIR proteins. Raw GST values are presented in S1 Fig. Cross-reactivity was ruled
out in a pilot study analyzing a subset of plasmas in singleplex and multiplex. Samples in IN
were analyzed with identical protocols and instruments.
Cellular stimulation assays
Except where indicated, all reagents were purchased from BD Biosciences. PBMCs were
thawed, rested for 10–12 h and viability assessed with Guava ViaCount Reagent (Millipore).
Only samples with viability>70% were used for assays. Half a million cells per well were resus-
pended in RPMI-1640medium plus 10% fetal bovine serum (culture medium) and incubated
with PvLP1 or PvLP2 (5 μg/mL). Culture mediumwas used as negative control and anti-CD3
as the positive control. After 12 h, an aliquot of 30 μL of culture medium supernatant was col-
lected to measure secreted cytokines, while an equal volume of media containing GolgiPlug
was added for additional (4 h) incubation. PBMCs were stained with LIVE/DEADFixable Vio-
let Dead (Life Technologies), anti-CD14 Pacific Blue, anti-CD19 Horizon V450, anti-CD4 allo-
phycocyanin (APC) and anti-CD8 Peridinin Chlorophyll Protein Complex (PerCP). After
washing, cells were fixed and permeabilizedwith Cytofix/Cytoperm, and incubated with anti-
CD3 phycoerythrin (PE)-Cy7, anti-interferon (IFN)-γ PE and anti-CD69 fluorescein isothiocy-
anate (FITC). Cells were acquired in a LSRFortessa flow cytometer and data were analyzed by
FlowJo (FlowJo LLC, OR, USA). Gating strategy is provided in S2 Fig. Supernatants were
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frozen at -80°C until Luminex analysis with the CytokineMagnetic 30-Plex Panel (Invitrogen),
according to manufacturer’s instructions.
Plasmodium spp. detection by PCR
Samples from BR, CO, GT, and half of the samples from PNG were analyzed at the Istituto
Superiore di Sanità (Rome, Italy), as described [12]. The threshold for positivity for each spe-
cies was established as a cycle threshold<45, according to negative controls. P. vivax diagnosis
for IN samples was performed in Delhi following Rome’s protocol adapted for the instrument
sensitivity (3rd step amplification 72°C for 25 sec instead of 72°C for 5 sec). Approximately half
of the PNG samples were analyzed for submicroscopic infections in Madang, following a simi-
lar protocol to Rome’s [49], except that the threshold for positivity for each species was estab-
lished as cycle threshold<40, according to negative controls. DNA was extracted from whole
blood-spot filter paper.
Definitions and statistical methods
Any Plasmodium infectionwas defined as a positive smear by microscopy and/or positive
PCR. One-way ANOVA test was used to evaluate the differences in antibody levels among
countries, and Chi-squared or Fisher’s exact tests to evaluate the differences in percentages of
individuals with a positive antibody response (values above the mean plus 3 standard devia-
tions [SD] of Spanish controls, cutoff).To assess the differences on antibody levels between
non-pregnant and pregnant women at recruitment and delivery, multilevel mixed-effects linear
regressions were estimated with the samples from the five countries. Timepoint (recruitment,
delivery and postpartum) was the fixed independent variable, while inter-site (country of ori-
gin) and inter-subject variability were estimated as random parts. To study the association
between antibody levels and pregnancy variables, univariate (only adjusted for country of ori-
gin) and multivariate linear regression models were estimated with the variables country, age,
gestational age, gravidity (number of previous gestations) and P. vivax or P. falciparum infec-
tion during pregnancy (only accounted past or present infections but not future infections).
The correlation between IgG responses to different antigens was evaluated with the Spearman's
rank test. The association between IgG levels at enrolment and future malaria infections was
evaluated with logistic regressionmodels. The association between antibody responses at enrol-
ment and delivery, and Hb levels at delivery and birth weight, were analyzed using univariate
and multivariate linear regression models, adjusted by country, Hb at recruitment, gestational
age at recruitment, age, gravidity and past or present Plasmodium infection during pregnancy.
For the cellular and cytokine analyses, deviation from normality was tested using the Skewness
and kurtosis test. Because none of the variables except IL-13 presented a normal distribution,
data was presented as medians and comparisons between groups were done using the
U-Mann-Whitney test. Cytokine/chemokine production in culture supernatants of unstimu-
lated samples (medium) was not subtracted from the stimulated samples but shown side by
side as it is possibly biologically relevant. Significancewas defined at p<0.05. Crude p values
are interpreted for internal coherence, consistency of results and biological plausibility. Analy-
ses were performed using Stata/SE 10.1 (College Station, TX, USA).
Supporting Information
S1 Fig. Human IgG antibodies against GST were detected by Luminex in peripheral plasma
at recruitment.Antibody levels are represented as median fluorescence intensity (MFI).
Median (white line), and 25th and 75th percentiles (lower and upper hinge respectively) are
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represented in the box. Outside values are not displayed in the graph.
(GIF)
S2 Fig. Gating strategy. After exclusion of debris and doublets, lymphocytes were displayed
according to CD3 expression and a dump channel containing a viability marker, CD14 and
CD19. Live CD3+ T cells were then gated for CD4+ and CD8+ and intracytoplasmic expression
of IFN-γ and CD69 was assessed in each of the populations.
(JPG)
S1 Table. Characteristicsof the one-exon vir genes and proteins selected for cloning and
expression, and primer sequencesused for gDNA amplification.
(DOCX)
S2 Table. Characteristicsof the var2csa-like vir genes and proteins selected for cloning and
expression, and primer sequencesused for gDNA amplification.
(DOCX)
S3 Table. Baseline characteristicsof study population.
(DOCX)
S4 Table. Number of samples for which anti-VIR antibody responseswere analyzedby
country, timepoint and antigen.
(DOCX)
S5 Table. Correlation of anti-VIR responseswith other anti-Plasmodium responses.
(DOCX)
S6 Table. Effect of time of bleeding on antibody levels.
(DOCX)
S7 Table. Peptide sequences of the long peptides (PvLP).P. vivax long synthetic peptides
(PvLP) representing conserved central core (PvLP1) and C-terminal (PvLP2) VIR motifs.
Derivatized diethylene glycol (DEG,Merck Chemicals,Nottingham,UK) was inserted in
between the different individual segments.
(DOCX)
S1 Checklist.STROBE checklist for cohort studies.
(DOC)
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